241 related articles for article (PubMed ID: 21915626)
1. A new malaria antigen produces partial protection against Plasmodium yoelii challenge.
Zhang Y; Qi Y; Li J; Liu S; Hong L; Lin T; Long C; Su XZ
Parasitol Res; 2012 Apr; 110(4):1337-45. PubMed ID: 21915626
[TBL] [Abstract][Full Text] [Related]
2. Merozoite surface protein 4/5 provides protection against lethal challenge with a heterologous malaria parasite strain.
Goschnick MW; Black CG; Kedzierski L; Holder AA; Coppel RL
Infect Immun; 2004 Oct; 72(10):5840-9. PubMed ID: 15385485
[TBL] [Abstract][Full Text] [Related]
3. Rhop-3 protein conservation among Plasmodium species and induced protection against lethal P. yoelii and P. berghei challenge.
Wang T; Fujioka H; Drazba JA; Sam-Yellowe TY
Parasitol Res; 2006 Aug; 99(3):238-52. PubMed ID: 16541261
[TBL] [Abstract][Full Text] [Related]
4. Novel antigen identification method for discovery of protective malaria antigens by rapid testing of DNA vaccines encoding exons from the parasite genome.
Haddad D; Bilcikova E; Witney AA; Carlton JM; White CE; Blair PL; Chattopadhyay R; Russell J; Abot E; Charoenvit Y; Aguiar JC; Carucci DJ; Weiss WR
Infect Immun; 2004 Mar; 72(3):1594-602. PubMed ID: 14977966
[TBL] [Abstract][Full Text] [Related]
5. Immunization with recombinant Plasmodium yoelii merozoite surface protein 4/5 protects mice against lethal challenge.
Kedzierski L; Black CG; Coppel RL
Infect Immun; 2000 Oct; 68(10):6034-7. PubMed ID: 10992516
[TBL] [Abstract][Full Text] [Related]
6. Protective immunization with a novel membrane protein of Plasmodium yoelii-infected erythrocytes.
Burns JM; Adeeku EK; Dunn PD
Infect Immun; 1999 Feb; 67(2):675-80. PubMed ID: 9916076
[TBL] [Abstract][Full Text] [Related]
7. Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge.
Rénia L; Ling IT; Marussig M; Miltgen F; Holder AA; Mazier D
Infect Immun; 1997 Nov; 65(11):4419-23. PubMed ID: 9353014
[TBL] [Abstract][Full Text] [Related]
8. Effects of transmission-blocking vaccines simultaneously targeting pre- and post-fertilization antigens in the rodent malaria parasite Plasmodium yoelii.
Zheng L; Pang W; Qi Z; Luo E; Cui L; Cao Y
Parasit Vectors; 2016 Aug; 9(1):433. PubMed ID: 27502144
[TBL] [Abstract][Full Text] [Related]
9. Enhanced protection against malaria by a chimeric merozoite surface protein vaccine.
Shi Q; Lynch MM; Romero M; Burns JM
Infect Immun; 2007 Mar; 75(3):1349-58. PubMed ID: 17158895
[TBL] [Abstract][Full Text] [Related]
10. Alteration in host cell tropism limits the efficacy of immunization with a surface protein of malaria merozoites.
Shi Q; Cernetich A; Daly TM; Galvan G; Vaidya AB; Bergman LW; Burns JM
Infect Immun; 2005 Oct; 73(10):6363-71. PubMed ID: 16177307
[TBL] [Abstract][Full Text] [Related]
11. Plasmodium berghei circumvents immune responses induced by merozoite surface protein 1- and apical membrane antigen 1-based vaccines.
Yoshida S; Nagumo H; Yokomine T; Araki H; Suzuki A; Matsuoka H
PLoS One; 2010 Oct; 5(10):e13727. PubMed ID: 21060850
[TBL] [Abstract][Full Text] [Related]
12. Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection.
Alaro JR; Lynch MM; Burns JM
Vaccine; 2010 Oct; 28(42):6876-84. PubMed ID: 20709001
[TBL] [Abstract][Full Text] [Related]
13. Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection.
Narum DL; Ogun SA; Thomas AW; Holder AA
Infect Immun; 2000 May; 68(5):2899-906. PubMed ID: 10768987
[TBL] [Abstract][Full Text] [Related]
14. Immunization with the MAEBL M2 Domain Protects against Lethal Plasmodium yoelii Infection.
Leite JA; Bargieri DY; Carvalho BO; Albrecht L; Lopes SC; Kayano AC; Farias AS; Chia WN; Claser C; Malleret B; Russell B; Castiñeiras C; Santos LM; Brocchi M; Wunderlich G; Soares IS; Rodrigues MM; Rénia L; Costa FT
Infect Immun; 2015 Oct; 83(10):3781-92. PubMed ID: 26169268
[TBL] [Abstract][Full Text] [Related]
15. Identification of two new protective pre-erythrocytic malaria vaccine antigen candidates.
Limbach K; Aguiar J; Gowda K; Patterson N; Abot E; Sedegah M; Sacci J; Richie T
Malar J; 2011 Mar; 10():65. PubMed ID: 21410955
[TBL] [Abstract][Full Text] [Related]
16. Persistence of protective immunity to malaria induced by DNA priming and poxvirus boosting: characterization of effector and memory CD8(+)-T-cell populations.
Sedegah M; Brice GT; Rogers WO; Doolan DL; Charoenvit Y; Jones TR; Majam VF; Belmonte A; Lu M; Belmonte M; Carucci DJ; Hoffman SL
Infect Immun; 2002 Jul; 70(7):3493-9. PubMed ID: 12065488
[TBL] [Abstract][Full Text] [Related]
17. Suppression of lethal Plasmodium yoelii malaria following protective immunization requires antibody-, IL-4-, and IFN-gamma-dependent responses induced by vaccination and/or challenge infection.
Petritus PM; Burns JM
J Immunol; 2008 Jan; 180(1):444-53. PubMed ID: 18097046
[TBL] [Abstract][Full Text] [Related]
18. Oral immunization with a combination of Plasmodium yoelii merozoite surface proteins 1 and 4/5 enhances protection against lethal malaria challenge.
Wang L; Goschnick MW; Coppel RL
Infect Immun; 2004 Oct; 72(10):6172-5. PubMed ID: 15385527
[TBL] [Abstract][Full Text] [Related]
19. Recombinant peptide replicates immunogenicity of synthetic linear peptide chimera for use as pre-erythrocytic stage malaria vaccine.
Silva-Flannery LM; Cabrera-Mora M; Jiang J; Moreno A
Microbes Infect; 2009 Jan; 11(1):83-91. PubMed ID: 19015042
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the protective efficacy of yeast-derived and Escherichia coli-derived recombinant merozoite surface protein 4/5 against lethal challenge by Plasmodium yoelii.
Kedzierski L; Black CG; Stowers AW; Goschnick MW; Kaslow DC; Coppel RL
Vaccine; 2001 Sep; 19(32):4661-8. PubMed ID: 11535314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
